Publication Details
Abstract
Objective: Heart failure (HF) is an expanding global health issue, impacting millions of people worldwide. Type II diabetes mellitus and polycystic ovarian syndrome are metabolic illness that are linked to asprosin, a newly discovered fasting- induced glucogenic adipokine. The purpose of this research was to evaluate asprosin levels in the blood when heart failure is present. Methods: One hundred patients with heart failure were included in the heart failure group, while one hundred participants with health check-ups were included in the non-heart failure group. Blood samples were drawn from both groups to measure serum asprosin concentrations, and the corresponding clinical data were gathered for further statistical evaluation. Results: In the HF group, the concentration of serum asprosin was noticeably greater than HF -free group, and this difference was shown to be significant in statistical terms (P < 0.001). We classified all the participants into three quartiles based on the serum Asprosin levels. An increase in the serum asprosin levels was associated with an increase in the HF incidence rate across all three groups (P < 0.001). The correlation between N-terminal pro-B-type natriuretic peptide and the levels of serum asprosin is positive (P < 0.05), while LVEF and serum asprosin levels are negatively correlated (P < 0.001). Evidence from a dichotomous logistic regression analysis shows there are two separate risk variables for HF: asprosin and age (OR = 1.010, 95% CI: 1.003–1.018; OR = 1.058, 95% CI:1.004–1.665, respectively). Novelty: Serum asprosin concentrations were significantly increased in HF patients. Asprosin serum levels serve as independent risk indicator for HF, and HF diagnosis accuracy can be enhanced by measuring asprosin and NT-proBNP levels simultaneously.